AIM ImmunoTech Inc. Common Stock AIM 深 滬
已收盤 02-06 16:00:00 美东时间
1.14
-0.090
-7.32%
華盛通- 最 高1.25
- 今 開1.25
- 成交量 155.51万股
- 最 低 1.06
- 昨 收 1.23
- 總市值 373.51万
- 52周最高 20.3297
- 市盈率 靜 --
- 換手率 47.46%
- 52周最低 1.03
- 委 比 -33.33%
- 總股本 327.64万
- 歷史最高 20.3297
- 量 比 0.11
- 振 幅 15.45%
- 歷史最低 1.03
- 每 手 1
- 風險率 2.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AIM ImmunoTech Reports Data From Ongoing Phase 2 Clinical Study Evaluating Ampligen Combined With AstraZeneca's Anti-PD-L1 Immune Checkpoint Inhibitor Imfinzi For Metastatic Pancreatic Cancer Treatment
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported positive data in a year-end update from the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen® (rintatolimod) combined with
02-05 21:42
AIM ImmunoTech erhält US-Patent für Ampligen-Kombinationstherapie bei Krebs
AIM ImmunoTech erhält US-Patent für Ampligen-Kombinationstherapie bei Krebs AIM ImmunoTech Inc. hat ein US-Patent für Ampligen als Onkologie-Behandlung in Kombination mit Anti-PD-L1-Therapien bekanntgegeben. Das Patent läuft bis zum 9. August 2039. Disclaimer: This news brief was created by Public T
02-05 21:40
AIM ImmunoTech Secures U.S. Patent for Ampligen as Oncology Treatment in Combination with Anti-PD-L1 Therapies, Extending Protection to 2039
AIM ImmunoTech Secures U.S. Patent for Ampligen as Oncology Treatment in Combination with Anti-PD-L1 Therapies, Extending Protection to 2039 AIM ImmunoTech Inc. announced the granting of a U.S. patent covering Ampligen as an oncology treatment in combination with anti-PD-L1 therapies, similar to its
02-05 21:40
AIM ImmunoTech Launches $12 Million Rights Offering
AIM ImmunoTech Launches $12 Million Rights Offering AIM ImmunoTech Inc. has announced details regarding its proposed rights offering, through which the company plans to raise up to $12 million in gross proceeds if fully subscribed. The rights offering will be available to holders of record of Common
01-26 15:25
AIM ImmunoTech Announces $12M Proposed Rights Offering With Series G Convertible Preferred Stock And Warrants; Record Date Feb. 4, 2026 And Subscription Period Feb. 5 To 23, 2026
AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and
01-24 02:27
AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering
<b>Aim ImmunoTech Announces Rights Offering</b> Aim ImmunoTech Inc. has announced a rights offering to raise up to $12 million (net proceeds) by issuing shares of Series G Convertible Preferred Stock and warrants. Subscribers can purchase one unit (Preferred Stock + 1,492 Common Stock warrants) for $1,000, with conversion and exercise prices set at $1.34 per share. Key dates include a Record Date of February 4, 2026, and a subscription period f...
01-23 18:22
AIM ImmunoTech Declares 1-For-1,000 Stock Dividend For Shareholders And Option/Warrant Holders
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every
2025-12-31 06:20
AIM ImmunoTech Announces Stock Dividend
AIM ImmunoTech Inc. (NYSE American: AIM) announced a stock dividend of one share of common stock for every 1,000 shares outstanding and one share for every outstanding option or warrant. The dividend will be issued to shareholders and Alternate Securities holders of record as of January 9, 2026, and distributed to DTCC on January 13, 2026. Fractional shares will be rounded down, with remaining fractions paid in cash based on a $1.305 per-share pr...
2025-12-30 22:10
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors ...
2025-12-17 02:17
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Inc. has published a new CEO Corner segment on its website, where Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company’s lead program, Ampligen® (rintatolimod), which is currently being evaluated in the DURIPANC Phase 1b/2 clinical trial in combination with AstraZeneca’s Imfinzi® (durvalumab). For more details, visit the company’s website.
2025-12-10 14:00
